MeSH term
Frequency | Condition_Probility | Adolescent | 12 | 0.0 |
Child | 6 | 0.0 |
Child, Preschool | 7 | 0.0 |
Female | 40 | 0.0 |
Hematologic Neoplasms/complications/therapy | 2 | 40.0 |
Humans | 77 | 0.0 |
Infant | 7 | 0.0 |
Male | 41 | 0.0 |
Research Support, Non-U.S. Gov't | 39 | 0.0 |
Adult | 28 | 0.0 |
Aged | 15 | 0.0 |
Blood Donors | 2 | 0.0 |
Cell Line | 4 | 0.0 |
Cells, Cultured | 7 | 0.0 |
Kinetics | 6 | 0.0 |
Middle Aged | 32 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Transplantation, Homologous | 10 | 1.0 |
Cyclic AMP/metabolism | 4 | 0.0 |
In Vitro | 4 | 0.0 |
Molecular Sequence Data | 8 | 0.0 |
Rats | 10 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Salmon | 10 | 37.0 |
Transfection | 5 | 0.0 |
Bone Marrow Cells/pathology | 2 | 3.0 |
*Hematopoietic Stem Cell Transplantation | 10 | 2.0 |
Histocompatibility Testing | 2 | 0.0 |
Treatment Outcome | 19 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Clinical Trials | 2 | 0.0 |
Graft vs Host Disease | 2 | 8.0 |
Hematopoietic Stem Cell Transplantation/*methods | 2 | 2.0 |
Leukemia/*therapy | 2 | 1.0 |
Recurrence | 5 | 0.0 |
Chronic Disease | 2 | 0.0 |
English Abstract | 4 | 0.0 |
Prospective Studies | 5 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Disease-Free Survival | 4 | 0.0 |
Risk | 2 | 0.0 |
*Transplantation Conditioning | 2 | 8.0 |
Combined Modality Therapy | 5 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Prognosis | 6 | 0.0 |
Survival Analysis | 7 | 0.0 |
Time Factors | 7 | 0.0 |
Transplantation, Autologous | 8 | 2.0 |
Hematopoietic Stem Cell Transplantation/adverse effects | 2 | 12.0 |
Incidence | 2 | 0.0 |
Risk Factors | 3 | 0.0 |
Animals | 21 | 0.0 |
Cohort Studies | 2 | 0.0 |
Hematopoietic Stem Cell Transplantation | 2 | 1.0 |
Retrospective Studies | 5 | 0.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Immunosuppressive Agents/administration & dosage | 2 | 7.0 |
Registries | 2 | 0.0 |
Survival Rate | 6 | 0.0 |
Transplantation Conditioning/methods | 2 | 9.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Follow-Up Studies | 5 | 0.0 |
*Graft Survival | 2 | 1.0 |
Tissue Donors | 3 | 1.0 |
Acute Disease | 3 | 0.0 |
Drug Resistance | 3 | 0.0 |
Graft vs Host Disease/complications/*drug therapy | 2 | 100.0 |
Remission Induction | 5 | 0.0 |
Salvage Therapy | 3 | 4.0 |
Binding, Competitive | 4 | 0.0 |
Calcitonin/*metabolism | 3 | 37.0 |
Receptors, Calcitonin/*metabolism | 2 | 22.0 |
Calcitonin/*pharmacology | 5 | 27.0 |
Calcium/blood | 6 | 2.0 |
Comparative Study | 11 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 8 | 0.0 |
Administration, Intranasal | 6 | 7.0 |
Double-Blind Method | 3 | 0.0 |
Ovariectomy | 2 | 1.0 |
*Hematopoietic Stem Cell Transplantation/adverse effects | 2 | 5.0 |
Amino Acid Sequence | 5 | 0.0 |
Base Sequence | 3 | 0.0 |
Calcitonin/metabolism/*pharmacology | 3 | 100.0 |
Hamsters | 2 | 0.0 |
Nasal Mucosa/*metabolism | 2 | 10.0 |
Enzyme Activation | 3 | 0.0 |
Adenylate Cyclase/*metabolism | 2 | 3.0 |
Species Specificity | 3 | 0.0 |
Age Factors | 2 | 0.0 |
Swine | 2 | 0.0 |
Receptors, Calcitonin | 4 | 44.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Transplantation, Homologous/adverse effects/mortality | 2 | 50.0 |
Drug Administration Schedule | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Radioimmunoassay | 4 | 0.0 |
Phosphates/blood | 2 | 3.0 |
Piperazines/*therapeutic use | 2 | 4.0 |
Pyrimidines/*therapeutic use | 2 | 4.0 |
Stem Cell Transplantation | 2 | 4.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Calcium/metabolism | 2 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
